HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ira Gantz Selected Research

trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamide

8/2007NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
4/2007Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.
10/2006Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ira Gantz Research Topics

Disease

27Type 2 Diabetes Mellitus (MODY)
01/2022 - 03/2015
16Body Weight (Weight, Body)
10/2021 - 06/2002
10Hypoglycemia (Reactive Hypoglycemia)
10/2021 - 01/2013
8Weight Loss (Weight Reduction)
10/2017 - 02/2006
5Heart Failure
12/2020 - 01/2013
4Cardiovascular Diseases (Cardiovascular Disease)
05/2021 - 10/2020
4Infections
01/2021 - 01/2020
3Myocardial Infarction
01/2022 - 11/2017
3Stroke (Strokes)
01/2022 - 11/2017
2Diabetes Mellitus
05/2021 - 04/2021
2Albuminuria
12/2020 - 01/2020
2Fournier Gangrene
06/2020 - 03/2020
2Obesity
12/2010 - 01/2008
1Chronic Renal Insufficiency
10/2021
1Hypovolemia
10/2021
1Venous Thromboembolism
06/2020
1Hypersensitivity (Allergy)
06/2020
1Pancreatitis
06/2020
1Ketosis
06/2020
1Neoplasms (Cancer)
06/2020
1Urinary Tract Infections (Urinary Tract Infection)
06/2020
1Necrotizing Fasciitis
03/2020
1Liver Diseases (Liver Disease)
01/2020
1Disease Progression
11/2017
1Weight Gain
10/2017
1Chronic Kidney Failure (Chronic Renal Failure)
06/2017
1Edema (Dropsy)
09/2016
1Flushing
04/2010
1Nausea
04/2010
1Body Weight Changes
05/2007
1Overweight
10/2006
1Inflammation (Inflammations)
03/2003

Drug/Important Bio-Agent (IBA)

13ertugliflozinIBA
01/2022 - 01/2020
122- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA
01/2021 - 11/2015
8Glucose (Dextrose)FDA LinkGeneric
05/2021 - 01/2013
7Metformin (Glucophage)FDA LinkGeneric
05/2021 - 09/2016
6Dipeptidyl-Peptidase IV InhibitorsIBA
11/2017 - 11/2015
5Sodium-Glucose Transporter 2 InhibitorsIBA
10/2021 - 01/2020
5Hypoglycemic Agents (Hypoglycemics)IBA
11/2017 - 03/2015
4Sodium-Glucose Transport ProteinsIBA
12/2020 - 01/2020
4Sitagliptin Phosphate (Januvia)FDA Link
01/2019 - 09/2016
4N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA
12/2010 - 01/2008
3Insulin (Novolin)FDA Link
01/2021 - 06/2017
3glimepiride (Amarel)FDA LinkGeneric
01/2020 - 10/2017
3trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamideIBA
08/2007 - 10/2006
2omega-Chloroacetophenone (Mace)IBA
01/2022 - 11/2017
2Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2020 - 01/2020
2Pharmaceutical PreparationsIBA
08/2017 - 05/2007
2Neuropeptide YIBA
08/2007 - 04/2007
2neuropeptide Y5 receptorIBA
08/2007 - 10/2006
1DiureticsIBA
12/2020
1SodiumIBA
03/2020
1AlbuminsIBA
01/2020
1CreatinineIBA
01/2020
1Insulin Glargine (Lantus)FDA Link
01/2019
1Glipizide (Glucotrol)FDA LinkGeneric
06/2017
1Pioglitazone (Actos)FDA Link
09/2016
1Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
11/2015
1CannabinoidsIBA
01/2008
1sibutramine (Meridia)FDA Link
08/2007
1Orlistat (Xenical)FDA Link
08/2007
1Hormones (Hormone)IBA
08/2007
1peptide YY (3-36)IBA
05/2007
1LeptinIBA
02/2006
1Melanocortin Receptors (Melanocortin Receptor)IBA
10/2005
1Agouti-Related ProteinIBA
04/2003
1MelanocortinsIBA
03/2003
1seven-transmembrane G-protein-coupled receptorIBA
06/2002
1Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA
06/2002

Therapy/Procedure

8Therapeutics
01/2021 - 01/2008
6Glycemic Control
04/2018 - 09/2016
2Caloric Restriction
12/2010 - 04/2007
1Secondary Prevention
12/2020
1Drug Therapy (Chemotherapy)
12/2010